Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
Commentary|Slideshows|January 30, 2025
Clinical Pearls: Discussing ADHD at Real Psychiatry
Check out these insights from clinicians at Real Psychiatry!
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
2
NDA Submission Complete: COMP360 Psilocybin for Treatment-Resistant Depression
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Updates on CTx-1301, NDA Resubmission After FDA Complete Response Letter
5